Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
Coya Therapeutics (NASDAQ: COYA) announces an upcoming conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease. The results will be simultaneously presented at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar and Dr. Stanley Appel from Houston Methodist Research Institute, with funding from the Alzheimer's Association, Gates Foundation, and National Institute on Aging.
Coya Therapeutics (NASDAQ: COYA) annuncia una prossima conferenza telefonica martedì 29 ottobre alle 8:00 ET per discutere i risultati di un trial clinico di Fase 2 controllato da placebo e avviato da investigatori sull'interleuchina-2 a basso dosaggio (LD IL-2) in pazienti con malattia di Alzheimer da lieve a moderata. I risultati verranno presentati simultaneamente alla 17esima Conferenza sulle sperimentazioni cliniche per la malattia di Alzheimer (CTAD24) a Madrid, Spagna. Lo studio è stato guidato dal Dr. Alireza Faridar e dal Dr. Stanley Appel dell'Houston Methodist Research Institute, con finanziamenti dall'Alzheimer's Association, dalla Gates Foundation e dal National Institute on Aging.
Coya Therapeutics (NASDAQ: COYA) anuncia una próxima conferencia telefónica el martes 29 de octubre a las 8 a.m. ET para discutir los resultados de un ensayo clínico de Fase 2 controlado por placebo e iniciado por investigadores sobre interleucina-2 de baja dosis (LD IL-2) en pacientes con enfermedad de Alzheimer de leve a moderada. Los resultados se presentarán simultáneamente en la 17ª Conferencia de Ensayos Clínicos sobre la Enfermedad de Alzheimer (CTAD24) en Madrid, España. El estudio fue dirigido por el Dr. Alireza Faridar y el Dr. Stanley Appel del Houston Methodist Research Institute, con financiamiento de la Alzheimer's Association, la Gates Foundation y el National Institute on Aging.
Coya Therapeutics (NASDAQ: COYA)는 오는 10월 29일 화요일 오전 8시 ET에 경미한 정도의 알츠하이머병 환자를 대상으로 한 플라시보 대조, 연구자 주도 2상 임상 시험의 결과를 논의하기 위한 전화 회의를 개최한다고 발표했습니다. 결과는 스페인 마드리드에서 열리는 제17회 알츠하이머병 임상 시험 회의(CTAD24)에서 동시에 발표될 예정입니다. 이 연구는 휴스턴 메서디스트 연구소의 Dr. Alireza Faridar와 Dr. Stanley Appel이 주도하였으며, 자금은 알츠하이머 협회, 게이츠 재단, 그리고 노인국에서 지원받았습니다.
Coya Therapeutics (NASDAQ: COYA) annonce une prochaine conférence téléphonique le mardi 29 octobre à 8h00 ET pour discuter des résultats d'un essai clinique de Phase 2 contrôlé par placebo et initié par des chercheurs sur l'interleukine-2 à faible dose (LD IL-2) chez des patients atteints de la maladie d'Alzheimer légère à modérée. Les résultats seront présentés simultanément lors de la 17e Conférence sur les essais cliniques sur la maladie d'Alzheimer (CTAD24) à Madrid, Espagne. L'étude a été dirigée par le Dr Alireza Faridar et le Dr Stanley Appel de l'Houston Methodist Research Institute, avec des financements de l'Alzheimer's Association, de la Gates Foundation et du National Institute on Aging.
Coya Therapeutics (NASDAQ: COYA) kündigt eine bevorstehende Telefonkonferenz am Dienstag, den 29. Oktober, um 8 Uhr ET an, um die Ergebnisse einer placebokontrollierten, von Ermittlern initiierten Phase-2-Studie zu niedrig dosiertem Interleukin-2 (LD IL-2) bei Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit zu diskutieren. Die Ergebnisse werden zeitgleich auf der 17. Konferenz über klinische Studien zur Alzheimer-Krankheit (CTAD24) in Madrid, Spanien, vorgestellt. Die Studie wurde von Dr. Alireza Faridar und Dr. Stanley Appel vom Houston Methodist Research Institute geleitet und erhielt Mittel von der Alzheimer Association, der Gates Foundation und dem National Institute on Aging.
- Study received funding support from major institutions including Alzheimer's Association, Gates Foundation, and National Institute on Aging
- Phase 2 trial reached completion stage with results ready for presentation
- None.
The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley Appel from the Houston Methodist Research Institute, and it received funding from the Alzheimer's Association, the Gates Foundation, and the National Institute on Aging, with additional support from Coya.
Dr. Faridar will present a summary of the clinical results on the conference call, and Coya’s Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D. will discuss the Company’s strategy. A question-and-answer session will follow.
The conference call will be available through a live webcast that can be accessed here. Participants who may be interested in asking a question during the question-and-answer session can also join the call by dialing 1-866-807-9684 (domestic) or 1-412-317-5415 (international) and asking to join the Coya Therapeutics conference call.
A webcast replay of the call will be available approximately one hour after the live call until October 29, 2025.
Event: |
CTAD Data Readout – Phase 2 Trial of LD-IL-2 in Patients with Mild to Moderate AD |
||
Presentation Date: |
Tuesday, October 29, 2024 |
||
Time: |
8:00 AM ET |
||
Register for Conference Call: |
About Alzheimer’s Disease
Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to
1. |
Alzheimer’s Association (www.alz.org) |
|||
2. |
Centers for Disease Control and Prevention (www.cdc.gov) |
About COYA 301
COYA 301 is the company’s proprietary investigational low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and is designed for subcutaneous administration. COYA 301 is an investigational product not yet approved by the FDA or any other regulatory agency.
About Coya Therapeutics, Inc.
Headquartered in
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 – the Company’s lead biologic investigational product or “Pipeline in a Product”– is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visit www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028411053/en/
Investor Contact
David
david@coyatherapeutics.com
CORE IR
Bret Shapiro
brets@coreir.com
561-479-8566
Media Contacts
For Coya Therapeutics:
Kati Waldenburg
media@coyatherapeutics.com
212-655-0924
Source: Coya Therapeutics, Inc.
FAQ
When will Coya Therapeutics (COYA) announce its Phase 2 Alzheimer's trial results?
What is the Phase 2 trial by Coya Therapeutics (COYA) investigating?